Bolt Biotherapeutics
BOLT
21 hedge funds and large institutions have $3.3M invested in Bolt Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
10.5% less ownership
Funds ownership: 41.89% → 31.39% (-10%)
13% less funds holding
Funds holding: 24 → 21 (-3)
23% less capital invested
Capital invested by funds: $4.28M → $3.3M (-$982K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$142K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.75K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.49K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.45K |
| 5 |
Citigroup
New York
|
+$1.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$556K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$356K |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$260K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$129K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88.5K |
BOLT Hedge Fund Activity: Q4 2025 in Review
21 of the 8,250 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2025, worth a combined $3.3M — down 23% from $4.28M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BOLT and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $142K. The largest seller was Vivo Capital, cutting an estimated $556K.
- 21 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2025, down from 24 in Q3 2025.
- Funds reported $3.3M of Bolt Biotherapeutics stock for Q4 2025, down 23% quarter-over-quarter.
- 3 funds opened new Bolt Biotherapeutics positions in Q4 2025 and 6 closed out, a net change of -3 holders.
- The largest Bolt Biotherapeutics buyer in Q4 2025 was Renaissance Technologies, an estimated $142K added.
- The largest Bolt Biotherapeutics seller in Q4 2025 was Vivo Capital, an estimated $556K sold.
Based on aggregated 13F filings for Q4 2025.